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Supplementary tables 
 
Campaigns and interventions 
During the conduct of the present trial from 2003 to 2009 many government driven 
health intervention campaigns occurred as is now usual in Guinea–Bissau and other 
West African countries (see Table A). We had field assistants who accompanied all 
the campaign teams in the study area to monitor who received the intervention. After 
the campaigns we interviewed the mother of children who had not been present to 
obtain information on whether they had received the intervention elsewhere. There 
were two measles vaccination campaigns in May 2006 and July 2009. With 
permission from the Ministry of Health the study participants were excluded from 
these campaigns. Hence, the field assistants accompanying the vaccination teams had 
household based lists of all the children in the study area which indicated whether the 
child was excluded from measles vaccine during the campaign because it participated 
in the present two dose measles vaccine trial. Only 2-3% of the participants had 
received an additional measles vaccine outside the study area (Table A). 
Subjects in the trial could have taken part in other randomised trials in the area (see 
Table A). Low birth weight (LBW) children took part in a trial of BCG at birth 
(ClinicalTrials.gov NCT00146302 and NCT00168610) (30), most normal birth 
weight children participated in trials of vitamin A supplementation administered at 
birth with BCG vaccine (ClinicalTrials.gov NCT00168597 and NCT00168610) 
(31,32) and many were involved in a trial of booster DTP vaccine after 18 months of 
age (ClinicalTrials.gov  NCT00244673).  
 
 
Table A: Estimated impact in the PP analysis of early two-dose measles vaccine 
(Group A) compared with measles vaccine at 9 months (Groups B+C) on 
mortality from 4.5 to 36 months of age in different arms of a concurrent trial or 
when children were censored for participation in various trials and campaign.  
 Mortality rate ratio (MRR) (A vs B 
plus C)  
Overall effect 0.69 (0.51-0.94) 
Trials MRR in different arms of a concurrent 
trial 
VAS at birth 0.98 (0.64-1.49)# VAS-at-birth 
trials Placebo 0.34 (0.17-0.69)# 
Booster DTP 0.95 (0.24-3.80) DTP booster 
trial No booster 0.75 (0.24-2.40) 
Campaigns and health service delivery MRR after censoring for participation in 
campaign 
BCG at birth 0.67 (0.45-0.99) 
Measles vaccine campaign 2006 0.70 (0.52-0.95) 
Measles vaccine campaign 2009 0.69 (0.51-0.94) 
Bed net distribution 2006 0.70 (0.50-0.96) 
Bed net distribution 2007 0.72 (0.53-0.98) 
Bed net impregnation 2006 0.71 (0.52-0.96) 
Bed net impregnation 2007 0.71 (0.52-0.96) 
OPV campaign 2004 0.60 (0.41-0.88) 
OPV campaign 2005 0.65 (0.46-0.93) 
VAS campaign 2004 0.69 (0.49-0.97) 
VAS campaign 2005 0.67 (0.49-0.93) 
1st VAS campaign 2006 0.69 (0.50-0.96) 
2nd VAS campaign 2006 0.69 (0.50-0.95) 
1st VAS campaign 2007 0.73 (0.53-1.00) 
2nd VAS campaign 2007 0.71 (0.52-0.95) 
1st VAS campaign 2008 0.71 (0.52-0.96) 
2nd VAS campaign 2008 0.70 (0.52-0.95) 
1st VAS campaign 2009 0.70 (0.52-0.95) 
Notes: Estimates are not adjusted for district; VAS=vitamin A supplementation. From 
2006 onwards the vitamin A supplementation campaigns have usually included 
treatment with mebendazole for children aged 1-4 years. # p=0.012, test of interaction 
of vitamin A supplementation-at-birth and early measles vaccine. 
Table B: The mortality rates and mortality rate ratio of recipients of early two-dose (Group A) compared with measles vaccine at 9 
months (Group B).  All children  
ITT Mortality rate per 100 person-years  
(deaths/person-days) [N] 
Age 
interval  
Early two-dose measles 
vaccine (Group A) 
Measles vaccine at 9 
months (Group B) 
ITT Mortality rate 
ratio (A/B) 
 
ITT Mortality rate 
ratio (A/B) 
(with censoring for 
measles infection) 
PP Mortality rate 
ratio (A/B) 
 
PP Mortality rate 
ratio (A/B) 
(with censoring for 
measles infection) 
4.5 to 9 
months  
      
Boys 2.6 (10/142341) [1084] 2.0 (8/144740) [1091] 1.26 (0.50-3.19)  1.42 (0.54-3.74) 1.26 (0.50-3.19) 1.42 (0.54-3.74) 
Girls 1.6 (6/137245) [1045] 3.4 (13/139281) [1062] 0.51 (0.19-1.35) 0.60 (0.22-1.65) 0.51 (0.19-1.35) 0.60 (0.22-1.65) 
All 2.1 (16/279586) [2129] 2.7 (21/284021) [2153] 0.80 (0.42-1.55) 0.94 (0.48-1.84) 0.80 (0.42-1.55) 0.94 (0.48-1.84) 
9 to 36 
months 
      
Boys  1.2 (26/762500) [1047] 1.3 (26/757189) [1055] 0.99 (0.58-1.71) 1.05 (0.60-1.83) 0.81 (0.46-1.44) 0.83 (0.46-1.47) 
Girls  1.1 (23/744638) [1012] 1.8 (35/723179) [1017] 0.64 (0.38-1.08) 0.67 (0.39-1.13) 0.58 (0.33-1.02) 0.61 (0.35-1.08) 
All 1.2 (49/1507138) [2059] 1.5 (61/1480368) [2072] 0.79 (0.54-1.15) 0.83 (0.56-1.21) 0.69 (0.46-1.02) 0.71 (0.47-1.06) 
       
4.5 to 36 
months 
      
Boys 1.5 (36/904841) [1084] 1.4 (34/901929) [1091] 1.06 (0.66-1.69) 1.13 (0.70-1.83) 0.92 (0.56-1.49) 0.95 (0.58-1.56) 
Girls 1.2 (29/881883) [1045] 2.0 (48/862460) [1062] 0.60 (0.38-0.95) 0.64 (0.40-1.03) 0.55 (0.34-0.90) 0.60 (0.37-0.98) 
All 1.3 (65/1786724) [2129] 1.7 (82/1764389) [2153] 0.79 (0.57-1.09) 0.84 (0.61-1.18) 0.71 (0.50-1.00) 0.75 (0.53-1.07) 
 
Table C: The mortality rates and mortality rate ratio of recipients of early two-dose (Group A) compared with measles vaccine at 9 
months (Group C).  All children  
ITT Mortality rate per 100 person-years  
(deaths/person-days) [N] 
Age 
interval  
Early two-dose measles 
vaccine (Group A) 
Measles vaccine at 9 
months (Group C) 
ITT Mortality rate 
ratio (A/C) 
 
ITT Mortality rate 
ratio (A/C) 
(with censoring for 
measles infection) 
PP Mortality rate 
ratio (A/C) 
 
PP Mortality rate 
ratio (A/C) 
(with censoring for 
measles infection) 
4.5 to 9 
months  
      
Boys 2.6 (10/142341) [1084] 3.4 (13/138192) [1060] 0.76 (0.33-1.74)  1.09 (0.44-2.68) 0.76 (0.33-1.74) 1.09 (0.44-2.68) 
Girls 1.6 (6/137245) [1045] 3.6 (14/140118) [1075] 0.43 (0.17-1.13) 0.46 (0.17-1.22) 0.43 (0.17-1.13) 0.46 (0.17-1.22) 
All 2.1 (16/279586) [2129] 3.5 (27/278310) [2135] 0.59 (0.32-1.10) 0.72 (0.38-1.37) 0.59 (0.32-1.10) 0.72 (0.38-1.37) 
9 to 36 
months 
      
Boys  1.2 (26/762500) [1047] 1.4 (28/749182) [1025] 0.91 (0.54-1.56) 0.94 (0.55-1.60) 0.75 (0.42-1.31) 0.76 (0.43-1.35) 
Girls  1.1 (23/744638) [1012] 1.4 (28/752870) [1036] 0.83 (0.48-1.44) 0.82 (0.47-1.42) 0.72 (0.40-1.28) 0.71 (0.40-1.26) 
All 1.2 (49/1507138) [2059] 1.4 (56/1502052) [2061] 0.87 (0.59-1.28) 0.88 (0.60-1.29) 0.73 (0.49-1.10) 0.74 (0.49-1.10) 
       
4.5 to 36 
months 
      
Boys 1.5 (36/904841) [1084] 1.7 (41/887374) [1060] 0.86 (0.55-1.35) 0.97 (0.61-1.54) 0.75 (0.47-1.19) 0.84 (0.52-1.36) 
Girls 1.2 (29/881883) [1045] 1.7 (42/892988) [1075] 0.70 (0.44-1.12) 0.71 (0.44-1.14) 0.63 (0.38-1.02) 0.63 (0.39-1.03) 
All 1.3 (65/1786724) [2129] 1.7 (83/1780362) [2135] 0.78 (0.57-1.08) 0.83 (0.60-1.16) 0.69 (0.49-0.96) 0.73 (0.52-1.03) 
 
 
Table D: Mortality rates and mortality rate ratios by district and health centre. 
 
Intention-to-treat analysis 
District MR per 100 person-years  
(deaths/person-days) 
Mortality rate 
ratio (A/(B+C)) 
Health 
Centre 
MR per 100 person-years  
(deaths/person-days) 
Mortality rate 
ratio (A/(B+C)) 
Bandim 1 1.8 (79/1595873) 0.90 (0.56-1.46)
Bandim 2 1.8 (34/676703) 0.54 (0.24-1.18) Bandim 1.8 (113/2272576) 0.78 (0.52-1.17)
Belem 1.0 (17/640095) 1.37 (0.52-3.60)
Mindara 1.0 (9/332304) 2.48 (0.66-9.22)
Belem &  
Mindara 1.0 (26/972399) 1.68 (0.78-3.64)
Cuntum 1 1.6 (63/1425578) 0.81 (0.47-1.40)
Cuntum 2 1.5 (28/660922) 0.25 (0.07-0.81) Cuntum 1.6 (91/2086500) 0.61 (0.37-0.99)
      
Combined estimate Adjusting for district 0.78 (0.59-1.05)  Adjusting for health centre 0.78 (0.59-1.04)
Main estimate Without adjusting for district 0.78 (0.59-1.04)    
Notes: Interaction tests: Districts: p-value=0.11; Health centres: p-value=0.09 
 
Per-protocol analysis 
District MR per 100 person-years  
(deaths/person-days) 
Mortality rate 
ratio (A/(B+C)) 
Health 
Centre 
MR per 100 person-years  
(deaths/person-days) 
Mortality rate 
ratio (A/(B+C)) 
Bandim 1 1.9 (77/1499671) 0.86 (0.53-1.40)
Bandim 2 1.8 (31/629137) 0.40 (0.16-0.98) Bandim 1.9 (108/2128808) 0.70 (0.46-1.07)
Belem 1.0 (17/601260) 1.31 (0.50-3.45)
Mindara 0.9 (8/308723) 1.92 (0.48-7.66)
Belem &  
Mindara 1.0 (25/909983) 1.48 (0.67-3.27)
Cuntum 1 1.6 (57/1332768) 0.69 (0.38-1.25)
Cuntum 2 1.6 (27/599123) 0.23 (0.07-0.77) Cuntum 1.6 (84/1931891) 0.52 (0.31-0.88)
      
Combined estimate Adjusting for district 0.70 (0.52-0.94)  Adjusting for health centre 0.70 (0.51-0.94)
Main estimate Without adjusting for district 0.69 (0.51-0.94)    
Notes: Interaction tests: Districts: p-value=0.11; Health centres: p-value=0.10 
Table E: The mortality rates and mortality rate ratio of recipients of early two-dose measles vaccine (Group A) compared with measles 
vaccine at 9 months (Groups B+C). Only children who had received vitamin A supplementation at birth in the vitamin A 
supplementation-at-birth trials 
ITT Mortality rate per 100 person-years (deaths/person-days) [N] Mortality rate ratio 
(A/(B+C))  
Intention-to-treat  
Mortality rate ratio 
(A/(B+C)) 
Per-protocol 
Age interval  
Early two-dose measles vaccine 
(Group A) 
Measles vaccine at 9 months 
(Groups B and C) 
  
4.5 to 9 months      
Boys 3.7 (7/68738) [526] 1.6 (6/135473) [1021] 2.38 (0.80-7.09) 2.38 (0.80-7.09) 
Girls 2.2 (4/65286) [496] 3.7 (13/126919) [972] 0.63 (0.21-1.96) 0.63 (0.21-1.96) 
All 3.0 (11/134024) [1022] 2.6 (19/262392) [1993] 1.20 (0.57-2.53) 1.20 (0.57-2.53) 
9 to 36 months     
Boys  1.5 (15/361254) [507] 1.4 (27/723239) [994] 1.13 (0.60-2.12) 0.91 (0.47-1.76) 
Girls  1.0 (10/357695) [481] 1.1 (20/681546) [936] 0.96 (0.45-2.06) 0.96 (0.43-2.14) 
All 1.3 (25/718949) [988] 1.2 (47/1404785) [1930] 1.05 (0.65-1.71) 0.92 (0.55-1.54) 
     
4.5 to 36 months     
Boys 1.9 (22/429992) [526] 1.4 (33/858712) [1021] 1.34 (0.78-2.29) 1.16 (0.66-2.01) 
Girls 1.2 (14/422981) [496] 1.5 (33/808465) [972] 0.82 (0.44-1.53) 0.80 (0.42-1.53) 
All 1.5 (36/852973) [1022] 1.4 (66/1667177) [1993] 1.07 (0.71-1.61) 0.98 (0.64-1.50) 
 
Table F: The mortality rates and mortality rate ratio of recipients of early two-dose measles vaccine (Group A) compared with measles 
vaccine at 9 months (Groups B+C). Only children who had received placebo at birth in the vitamin A supplementation-at-birth trials 
ITT Mortality rate per 100 person-years (deaths/person-days) [N] Age interval  
Early two-dose measles 
vaccine (Group A) 
Measles vaccine at 9 months 
(Groups B and C) 
Mortality rate ratio 
(A/(B+C))  
Intention-to-treat  
Mortality rate ratio 
(A/(B+C)) 
Per-protocol  
4.5 to 9 months      
Boys 0 (0/46578) [350] 1.9 (5/96630) [733] 0 (p=0.120)* 0 (p=0.120)* 
Girls 0 (0/42893) [329] 3.1 (8/94217) [715] 0 (p=0.066)* 0 (p=0.066)* 
All 0 (0/89471) [679] 2.5 (13/190847) [1448] 0 (p=0.009)* 0 (p=0.009)* 
9 to 36 months     
Boys  0.8 (6/258906) [344] 1.3 (18/520760) [711] 0.67 (0.26-1.68) 0.44 (0.15-1.31) 
Girls  0.9 (6/235657) [320] 1.7 (24/504044) [691] 0.54 (0.22-1.31) 0.43 (0.17-1.14) 
All 0.9 (12/494563) [664] 1.5 (42/1024804) [1402] 0.59 (0.31-1.12) 0.43 (0.21-0.89) 
     
4.5 to 36 months     
Boys 0.7 (6/305484) [350] 1.4 (23/617390) [733] 0.52 (0.21-1.29) 0.35 (0.12-1.02) 
Girls 0.8 (6/278550) [329] 2.0 (32/598261) [715] 0.40 (0.17-0.96) 0.33 (0.13-0.85) 
All 0.8 (12/584034) [679] 1.7 (55/1215651) [1448] 0.45 (0.24-0.84) 0.34 (0.17-0.68) 
Note: * log-rank test. 
Table G: The mortality rates and mortality rate ratio of recipients of early two-dose measles vaccine (Group A) compared with measles 
vaccine at 9 months (Groups B+C). Only children who had not participated in the vitamin A supplementation-at-birth trials 
ITT Mortality rate per 100 person-years (deaths/person-days) 
[N] 
Age interval  
Early two-dose measles 
vaccine (Group A) 
Measles vaccine at 9 months 
(Groups B and C) 
Mortality rate ratio 
(A/(B+C)) 
Intention-to-treat  
Mortality rate ratio 
(A/(B+C))  
Per-protocol 
4.5 to 9 months      
Boys 4.1 (3/27025) [208] 7.2 (10/50829) [397] 0.57 (0.16-2.07) 0.57 (0.16-2.07) 
Girls 2.5 (2/29066) [220] 3.8 (6/58263) [450] 0.66 (0.13-3.27) 0.66 (0.13-3.27) 
All 3.3 (5/56091) [428] 5.4 (16/109092) [847] 0.61 (0.22-1.66) 0.61 (0.22-1.66) 
9 to 36 months     
Boys  1.3 (5/142340) [196] 1.3 (9/262372) [375] 1.02 (0.34-3.06) 1.04 (0.34-3.16) 
Girls  1.7 (7/151286) [211] 2.4 (19/290459) [426] 0.71 (0.30-1.68) 0.61 (0.24-1.54) 
All 1.5 (12/293626) [407] 1.8 (28/552831) [801] 0.81 (0.41-1.59) 0.74 (0.36-1.49) 
     
4.5 to 36 months     
Boys 1.7 (8/169365) [208] 2.2 (19/313201) [397] 0.79 (0.35-1.80) 0.76 (0.33-1.76) 
Girls 1.8 (9/180352) [220] 2.6 (25/348722) [450] 0.71 (0.33-1.51) 0.63 (0.28-1.40) 
All 1.8 (17/349717) [428] 2.4 (44/661923) [847] 0.74 (0.42-1.30) 0.69 (0.39-1.22) 
 
 
 
  
Table H: The mortality rates and mortality rate ratio of recipients of early two-dose measles vaccine (Group A) compared with measles 
vaccine at 9 months (Groups B). Only children who had not received vitamin A supplementation at birth  
ITT Mortality rate per 100 person-years  
(deaths/person-days) [N] 
Age 
interval  
Early two-dose measles 
vaccine (Group A) 
Measles vaccine at 9 
months (Group B) 
ITT Mortality rate 
ratio (A/B) 
 
ITT Mortality rate 
ratio (A/B) 
(with censoring for 
measles infection) 
PP Mortality rate 
ratio (A/B) 
 
PP Mortality rate 
ratio (A/B) 
(with censoring for 
measles infection) 
4.5 to 9 
months  
      
Boys 1.5 (3/73603) [558] 2.4 (5/74789) [567] 0.55 (0.13-2.32)  0.52 (0.12-2.24) 0.55 (0.13-2.32) 0.52 (0.12-2.24) 
Girls 1.0 (2/71959) [549] 3.4 (7/75769) [578] 0.31 (0.06-1.56) 0.45 (0.08-2.40) 0.31 (0.06-1.56) 0.45 (0.08-2.40) 
All 1.3 (5/145562) [1107] 2.9 (12/150558) [1145] 0.42 (0.15-1.19) 0.49 (0.17-1.45) 0.42 (0.15-1.19) 0.49 (0.17-1.45) 
9 to 36 
months 
      
Boys  1.0 (11/401246) [540] 1.3 (14/392211) [548] 0.78 (0.35-1.71) 0.88 (0.39-1.98) 0.63 (0.27-1.48) 0.66 (0.28-1.57) 
Girls  1.2 (13/386943) [531] 2.3 (24/389429) [554] 0.55 (0.28-1.08) 0.59 (0.30-1.17) 0.45 (0.22-0.93) 0.49 (0.24-1.00) 
All 1.1 (24/788189) [1071] 1.8 (38/781640) [1102] 0.63 (0.38-1.05) 0.69 (0.41-1.16) 0.51 (0.30-0.89) 0.54 (0.31-0.95) 
       
4.5 to 36 
months 
      
Boys 1.1 (14/474849) [558] 1.5 (19/467000) [567] 0.73 (0.37-1.46) 0.79 (0.39-1.61) 0.62 (0.30-1.29) 0.64 (0.30-1.33) 
Girls 1.2 (15/458902) [549] 2.4 (31/465198) [578] 0.50 (0.27-0.92) 0.56 (0.30-1.06) 0.42 (0.22-0.81) 0.48 (0.25-0.93) 
All 1.1 (29/933751) [1107] 2.0 (50/932198) [1145] 0.59 (0.37-0.93) 0.65 (0.41-1.04) 0.50 (0.31-0.80) 0.54 (0.33-0.88) 
 
Table I: The mortality rates and mortality rate ratio of recipients of early two-dose measles vaccine (Group A) compared with measles 
vaccine at 9 months (Groups C). Only children who had not received vitamin A supplementation at birth  
ITT Mortality rate per 100 person-years  
(deaths/person-days) [N] 
Age 
interval  
Early two-dose measles 
vaccine (Group A) 
Measles vaccine at 9 
months (Group C) 
ITT Mortality rate 
ratio (A/C) 
 
ITT Mortality rate 
ratio (A/C) 
(with censoring for 
measles infection) 
PP Mortality rate 
ratio (A/C) 
 
PP Mortality rate 
ratio (A/C) 
(with censoring for 
measles infection) 
4.5 to 9 
months  
      
Boys 1.5 (3/73603) [558] 5.0 (10/72670) [563] 0.30 (0.08-1.10)  0.49 (0.12-1.95) 0.30 (0.08-1.10) 0.49 (0.12-1.95) 
Girls 1.0 (2/71959) [549] 3.3 (7/76711) [587] 0.30 (0.06-1.44) 0.34 (0.07-1.68) 0.30 (0.06-1.44) 0.34 (0.07-1.68) 
All 1.3 (5/145562) [1107] 4.2 (17/149381) [1150] 0.30 (0.11-0.82) 0.42 (0.15-1.18) 0.30 (0.11-0.82) 0.42 (0.15-1.18) 
9 to 36 
months 
      
Boys  1.0 (11/401246) [540] 1.2 (13/390921) [538] 0.80 (0.36-1.78) 0.84 (0.37-1.91) 0.65 (0.27-1.55) 0.69 (0.29-1.67) 
Girls  1.2 (13/386943) [531] 1.7 (19/405074) [563] 0.71 (0.35-1.44) 0.69 (0.34-1.39) 0.62 (0.29-1.32) 0.61 (0.29-1.28) 
All 1.1 (24/788189) [1071] 1.5 (32/795995) [1101] 0.74 (0.44-1.26) 0.74 (0.44-1.27) 0.63 (0.36-1.11) 0.63 (0.36-1.12) 
       
4.5 to 36 
months 
      
Boys 1.1 (14/474849) [558] 1.8 (23/463591) [563] 0.59 (0.30-1.14) 0.73 (0.36-1.47) 0.50 (0.25-1.01) 0.62 (0.30-1.30) 
Girls 1.2 (15/458902) [549] 2.0 (26/481785) [587] 0.60 (0.32-1.13) 0.60 (0.32-1.15) 0.53 (0.27-1.04) 0.54 (0.27-1.06) 
All 1.1 (29/933751) [1107] 1.9 (49/945376) [1150] 0.59 (0.37-0.94) 0.65 (0.41-1.05) 0.51 (0.32-0.84) 0.57 (0.35-0.94) 
 
 
 
